CRISPR Therapeutics AG
CRSP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $5 | $3 | $6 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $5 | $3 | $5 |
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | -90.5% | 84,762.4% | -100% | – |
| Gross Profit | -$0 | $0 | -$0 | $1 |
| % Margin | -215% | 64.8% | -25,186.7% | 88.9% |
| EBITDA | -$0 | -$0 | -$1 | $0 |
| % Margin | -1,278% | -54.8% | -148,850.7% | 42.9% |
| Net Income | -$0 | -$0 | -$1 | $0 |
| % Margin | -1,046.4% | -41.5% | -149,122.7% | 41.4% |
| EPS Diluted | -4.34 | -1.94 | -8.36 | 4.7 |
| % Growth | -123.7% | 76.8% | -277.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$1 | $0 |